Sleeve Gastrectomy for Morbid-Obesity Sequelae After Transplantation (SG-4MOST)

This is an interventional treatment trial for Liver Transplantation Read More

Inclusion Criteria:

• actively listed for liver transplantation at University Health Network
• BMI at screening of a) >40; or b) BMI >35 and 1 obesity-related complication [diabetes (defined as hyperglycemia requiring medication(s) for control), hypertension (defined as a persistently elevated systolic pressure greater than 140 mmHg and/or requiring medication(s) for control), hypercholesterolemia (defined as elevated lipids requiring medication for control)] OR a diagnosis of Non Alcoholic Fatty Liver Disease (defined as the presence of a fatty liver on imaging without a secondary cause such as alcohol abuse) or Non Alcoholic Steatohepatitis
• upper endoscopy showing no contraindications to a sleeve gastrectomy procedure

Exclusion Criteria:

• • Listed for re-transplantation, or transplantation of another organ (eg. kidney).

  • Previous bariatric surgery.
  • Contraindication to undergoing sleeve gastrectomy such as severe gastroesophageal reflux disease or Barrett's Esophagus
  • MELD (Model End-Stage Liver Disease) score > 35 at the time of transplantation
  • Presence of any condition that in the opinion of the investigator(s) could compromise the patient's ability to comply with study procedures
  • Patients with a BMI <32 at transplant or having weight loss of 20% or more (pre-transplant estimated dry body weight compared to estimated dry body weight at screening)
  • Presence of any other condition that, in the opinion of the investigator(s), could compromise the patient's ability to safely undergo, or benefit from, the SG procedure (eg. significant sarcopenia)